SCHEMBL469490

SCHEMBL469490

CC(=O)Nc1ccc(O)c(/C=N/c2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.55
MAPT P10636 5/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 3/20 0.49
POLB P06746 2/20 0.49
HTT P42858 1/20 0.49
PLEC Q15149 1/20 0.49
ASF1A Q9Y294 1/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
TSHR P16473 1/20 0.46
PABPC1 P11940 1/20 0.46
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11489876 0.89 KMT2A (0.52) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11375793 0.89 KMT2A (0.52) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL10061888 0.78 ASF1A (0.50) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11804643 0.78 SMN1; SMN2 (0.68) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11804637 0.78 SMN1; SMN2 (0.68) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL974694 0.76 PKM (0.51) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL18591033 0.76 ALDH1A1 (0.44) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL12793453 0.76 CA1 (0.60) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15382226 0.75 SMN1; SMN2 (0.68) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11804653 0.75 SMN1; SMN2 (0.68) KMT2AMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2614091-B1 CATALYST FOR POLYMERIZING NORBORNENE MONOMERS AND A METHOD FOR PRODUCING NORBORNENE POLYMER SHOWA DENKO KK (JP) 2016-04-20 EP disclosed
US-20130059993-A1 CATALYST FOR POLYMERIZATION OF NORBORNENE MONOMERS, METHOD FOR PRODUCING NORBORNENE POLYMER, METHOD FOR PRODUCING NORBORNENE COPOLYMER, NORBORNENE POLYMER AND TRANSITION METAL COMPLEX SHOWA DENKO K.K. (JP) 2013-03-07 US disclosed
US-20130059993-A1 CATALYST FOR POLYMERIZATION OF NORBORNENE MONOMERS, METHOD FOR PRODUCING NORBORNENE POLYMER, METHOD FOR PRODUCING NORBORNENE COPOLYMER, NORBORNENE POLYMER AND TRANSITION METAL COMPLEX SHOWA DENKO K.K. (JP) 2013-03-07 US disclosed
WO-2012033227-A2 CATALYST FOR POLYMERIZING NORBORNENE MONOMERS AND A METHOD FOR PRODUCING NORBORNENE POLYMER SHOWA DENKO K.K. (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059993-A1 CATALYST FOR POLYMERIZATION OF NORBORNENE MONOMERS, METHOD FOR PRODUCING NORBORNENE POLYMER, METHOD FOR PRODUCING NORBORNENE COPOLYMER, NORBORNENE POLYMER AND TRANSITION METAL COMPLEX NNMT, PPOX, DNMT1 KMT2A 1417/4885MAPT 1168/4885NPC1 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.